Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2020, Vol. 47 Issue (2): 183-188    DOI: 10.31083/j.ceog.2020.02.5229
Original Research Previous articles | Next articles
Prediction of severity of preeclampsia in Egyptian patients: role of neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and C-reactive protein
A. E. Kholeif1, *(), M. Y. Khamis1, S. Eltabakh2, R. S. Swilam3, A. Elhabashy1, R. EISherif1
1Departments of Obstetrics & Gynecology
2Medical Biochemistry
3Clinical Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
Download:  PDF(2163KB)  ( 237 ) Full text   ( 13 )
Export:  BibTeX | EndNote (RIS)      
Abstract  Objective: In this study, the authors aimed to compare and correlate neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and C-reactive protein (CRP) levels in Egyptian patients with different degrees of preeclampsia (PE). Materials and Methods: The authors recruited 105 Egyptian pregnant women with gestational age ≥ 34 weeks. They were divided into 35 normotensive pregnant and 70 PE women, further subdivided into 35 mild and 35 severe PE cases according to ACOG criteria. Results: There was no statistically significant difference between patients with PE and healthy pregnant women as regards to NLR. PLR showed statistically significant difference between the control and severe PE cases and between mild and severe PE cases. CRP levels showed a statistically significant difference between the control and mild PE cases and between the control and severe PE cases. Conclusion: CRP was more sensitive and specific than PLR to predict PE in pregnant females, hence it can be used in prediction of PE. PLR was more sensitive but less specific than CRP to predict severity of PE in pregnant females, therefore PLR can be used for early prediction of severity. NLR cannot be used as a marker for prediction of PE or its severity.
Key words:  Preeclampsia      Neutrophil/lymphocyte ratio (NLR)      platelet/lymphocyte ratio (PLR)      C-reactive protein (CRP)     
Published:  15 April 2020     
*Corresponding Author(s):  A. E. Kholeif     E-mail:  alykholeif@yahoo.com

Cite this article: 

A. E. Kholeif, M. Y. Khamis, S. Eltabakh, R. S. Swilam, A. Elhabashy, R. EISherif. Prediction of severity of preeclampsia in Egyptian patients: role of neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and C-reactive protein. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 183-188.

URL: 

https://ceog.imrpress.com/EN/10.31083/j.ceog.2020.02.5229     OR     https://ceog.imrpress.com/EN/Y2020/V47/I2/183

Table 1  — Comparison among the three studied groups according to fetal outcome.
Group I (n = 35) Group II (n = 35) Group III (n = 35) Test of Sig. p
No. % No. % No. %
Neonatal birth weight (Kg)
Min. - Max. 1.30 - 4.0 1.30 - 4.20 1.10 - 3.60 F= 11.293* <0.001*
Mean ± SD. 2.98 ± 0.45 2.85 ± 0.63 2.32 ± 0.73
Median 3.0 2.90 2.45
Sig.bet.Grps p1=0.373, p2<0.001*, p3=0.001*
Apgar 1 min.
Min. - Max. 4.0 - 7.0 5.0 - 7.0 2.0 - 8.0 H= 10.710* 0.005*
Mean ± SD. 6.83 ± 0.57 6.86 ± 0.49 6.26 ± 1.27
Median 7.0 7.0 7.0
Sig.bet.Grps p1=0.808, p2=0.007*, p3=0.003*
Apgar 5 min.
Min. - Max. 8.0 - 9.0 7.0 - 9.0 6.0 - 9.0 H= 15.996* <0.001*
Mean ± SD. 8.97 ± 0.17 8.86 ± 0.43 8.40 ± 0.95
Median 9.0 9.0 9.0
Sig.bet.Grps p1=0.350, p2<0.001*, p3=0.004*
Admission to NICU
No 33 94.3 32 91.4 22 62.9 χ2= 14.885* 0.001*
Yes 2 5.7 3 8.6 13 37.1
Sig.bet.Grps FE p1=1.000, p2=0.001*, p3=0.004*
Table 2  — Comparison among the three studied groups according to different CBC parameters.
CBC Group I (n = 35) Group II (n = 35) Group III (n = 35) F p
Hemoglobin (g/dl)
Min. - Max. 7.90 - 14.30 8.0 - 13.50 5.40 - 16.10 4.018* 0.021*
Mean ± SD. 11.17 ± 1.23 11.17 ± 1.35 12.05 ± 1.83
Median 11.10 11.20 11.90
Sig. bet. grps. p1=0.987, p2=0.016*, p3=0.015*
WBCs (103/μL)
Min. - Max. 5.99 - 13.10 5.40 - 17.10 5.12 - 26.67 1.939 0.149
Mean ± SD. 9.58 ± 2.19 10.85 ± 3.14 11.35 ± 5.51
Median 8.70 10.91 10.90
Platelets (103/μL)
Min. - Max. 120.0 - 447.0 108.0 - 393.0 52.0 - 400.0 8.852* <0.001*
Mean ± SD. 230.17 ± 69.41 242.37 ± 73.36 171.69 ± 82.07
Median 218.0 247.0 159.0
Sig. bet. grps. p1=0.499, p2=0.002*, p3<0.001*
Table 3  — Comparison among the three studied groups according to neutrophils and lymphocytes.
Group 1 (n = 35) Group 2 (n = 35) Group 3 (n = 35) Test of Sig. p
Neutrophils (103/μL)
Min. - Max. 3.22 - 11.10 3.30 - 15.20 3.60 - 24.76 F = 2.353 0.100
Mean ± SD. 6.90 ± 2.14 8.08 ± 2.92 8.69 ± 4.88
Median 6.10 7.68 7.70
Lymphocytes (103/μL)
Min. - Max. 1.0 - 3.10 0.80 - 3.71 0.84 - 7.35 H = 3.918 0.141
Mean ± SD. 1.97 ± 0.53 2.13 ± 0.70 1.93 ± 1.12
Median 2.06 2.10 1.70
Table 4  — Comparison among the three studied groups according to NLR and PLR.
Group 1 (n = 35) Group 2 (n = 35) Group 3 (n = 35) H p
NLR 3.559 0.169
Min. - Max. 1.60 - 10.90 1.64 - 11.75 1.29 - 19.65
Mean ± SD. 3.92 ± 2.22 4.31 ± 2.58 5.28 ± 3.71
Median 3.0 3.43 4.08
PLR 7.386* 0.025*
Min. - Max. 46.15 - 260.53 56.84 - 287.69 16.15 - 292.10
Mean ± SD. 125.88 ± 52.42 126.37 ± 61.16 98.43 ± 59.11
Median 108.70 113.67 82.94
Sig.bet.Grps p1=0.784, p2=0.012*, p3=0.030*
Table 5  — Comparison among the three studied groups according to CRP.
Group 1 (n = 35) Group 2 (n = 35) Group 3 (n = 35) H p
CRP (mg/dL)
Min. - Max.

0.10 - 0.50

0.10 - 6.04

0.20 - 9.50

47.402*

<0.001*
Mean ± SD. 0.30 ± 0.13 1.17 ± 1.17 1.66 ± 1.73
Median 0.30 0.70 1.30
Sig.bet.Grps p1<0.001*, p2<0.001*, p3=0.645
Table 6  — Agreement (sensitivity, specificity) for PLR and CRP to predict cases (vs control).
AUC p 95% C.I Cut off Sensitivity Specificity PPV NPV
PLR 0.598 0.104 0.487 - 0.709 ≤77.5 35.71 85.71 83.3 40.0
CRP 0.905 <0.001* 0.850 - 0.961 >0.5 75.71 100.0 100.0 67.3
Table 7  — Agreement (sensitivity, specificity) for PLR and CRP to predict severe cases (vs mild).
AUC p 95% C.I Cut off Sensitivity Specificity PPV NPV
PLR 0.651* 0.030* 0.521 - 0.780 ≤101.364 65.71 62.86 63.9 64.7
CRP 0.611 0.109 0.477 - 0.746 >1 62.86 65.71 50.7 100.0
Figure 1.  — ROC curve for PLR and CRP to predict PE cases vs. control.

Figure 2.  —ROC curve for PLR and CRP to predict severe PE cases vs. mild.

[1] Sibai B., Dekker G., Kupferminc M.: “Pre-eclampsia”. Lancet, 2005, 365, 785.
doi: 10.1016/S0140-6736(05)17987-2 pmid: 15733721
[2] American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy: “Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy”. Obstet. Gynecol., 2013, 122, 1122.
doi: 10.1097/01.AOG.0000437382.03963.88 pmid: 24150027
[3] “Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy”. Am. J. Obstet. Gynecol., 2000, 183, S1.
pmid: 10920346
[4] Redman C.W., Sacks G.P., Sargent I.L.: “Preeclampsia: an excessive maternal inflammatory response to pregnancy”. Am. J. Obstet. Gynecol., 1999, 180, 499.
doi: 10.1016/s0002-9378(99)70239-5 pmid: 9988826
[5] Lynch A.M., Murphy J.R., Gibbs R.S., Levine R.J., Giclas P.C., Salmon J.E., et al.: “The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia”. BJOG, 2010, 117, 456.
doi: 10.1111/j.1471-0528.2009.02473.x pmid: 20074261
[6] Saito S., Sakai M., Sasaki Y., Tanebe K., Tsuda H., Michimata T.: “Quantitative analysis of peripheral blood Th0, Th1, Th2 and the Th1:Th2 cell ratio during normal human pregnancy and preeclampsia”. Clin. Exp. Immunol., 1999, 117, 550.
doi: 10.1046/j.1365-2249.1999.00997.x pmid: 10469061
[7] Orange S., Horvath J., Hennessy A.: “Preeclampsia is associated with a reduced interleukin-10 production from peripheral blood mononuclear cells”. Hypertens. Pregnancy, 2003, 22, 1.
doi: 10.1081/PRG-120016788 pmid: 12648438
[8] Holthe M.R., Staff A.C., Berge L.N., Lyberg T.: “Leukocyte adhesion molecules and reactive oxygen species in preeclampsia”. Obstet. Gynecol., 2004, 103, 913.
doi: 10.1097/01.AOG.0000124806.39111.ba pmid: 15121565
[9] Imtiaz F., Shafique K., Mirza S.S., Ayoob Z., Vart P., Rao S.: “Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population”. Int. Arch. Med., 2012, 5, 2.
doi: 10.1186/1755-7682-5-2 pmid: 22281066
[10] Balta S., Kurtoglu E., Kucuk U., Demirkol S., Ozturk C.: “Neutrophil-lymphocyte ratio as an important assessment too”. l. Expert. Rev. Cardiovasc. Ther., 2014, 12, 537.
doi: 10.1586/14779072.2014.902309 pmid: 24745892
[11] Bhutta H., Agha R., Wong J., Tang T.Y., Wilson Y.G., Walsh S.R.: “Neutrophil-lymphocyte ratio predicts medium-term survival following elective major vascular surgery: a cross-sectional study”. Vasc. Endovascular Surg., 2011, 45, 227.
doi: 10.1177/1538574410396590 pmid: 21289130
[12] Balta S., Celik T., Mikhailidis D.P., Ozturk C., Demirkol S., Aparci M., et al.: “The Relation Between Atherosclerosis and the Neutrophil-Lymphocyte Ratio”. Clin. Appl. Thromb. Hemost., 2016, 22, 405.
doi: 10.1177/1076029615569568 pmid: 25667237
[13] Ozturk C., Balta S., Balta I., Demirkol S., Celik T., Turker T., et al.: “Neutrophil-lymphocyte ratio and carotid-intima media thickness in patients with Behcet disease without cardiovascular involvement”. Angiology, 2015, 66, 291.
doi: 10.1177/0003319714527638 pmid: 24671132
[14] Turkmen K., Erdur F.M., Ozcicek F., Ozcicek A., Akbas E.M., Ozbicer A., et al.: “Platelet-to-lymphocyte ratio better predicts inflammation than neutrophil-to-lymphocyte ratio in end-stage renal disease patients”. Hemodial. Int., 2013, 17, 391.
doi: 10.1111/hdi.12040
[15] Tasoglu I., Sert D., Colak N., Uzun A., Songur M., Ecevit A.: “Neutrophil-lymphocyte ratio and the platelet-lymphocyte ratio predict the limb survival in critical limb ischemia”. Clin. Appl. Thromb. Hemost., 2014, 20, 645.
doi: 10.1177/1076029613475474 pmid: 23393289
[16] Cakmak B., Gulucu S., Aliyev N., Ozsoy Z., Nacar M., Koseoglu D.: “Neutrophil-lymphocyte and platelet-lymphocyte ratios in endometrial hyperplasia”. Obstet. Gynecol. Sci., 2015, 58, 157.
doi: 10.5468/ogs.2015.58.2.157 pmid: 25798430
[17] Yavuzcan A., Caglar M., Ustun Y., Dilbaz S., Ozdemir I., Yildiz E., et al.: “Mean platelet volume, neutrophil-lymphocyte ratio and plateletlymphocyte ratio in severe preeclampsia”. Ginekol. Pol., 2014, 85, 197.
[18] Proctor M.J., Morrison D.S., Talwar D., Balmer S.M., Fletcher C.D., O’Reilly D.S., et al.: “A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study”. Eur. J. Cancer, 2011, 47, 2633.
doi: 10.1016/j.ejca.2011.03.028
[19] Rebelo F., Schlussel M.M., Vaz J.S., Franco-Sena A.B., Pinto T.J., Bastos F.I., et al.: “C-reactive protein and later preeclampsia: systematic review and meta-analysis taking into account the weight status”. J. Hypertens., 2013, 31, 16.
doi: 10.1097/HJH.0b013e32835b0556 pmid: 23188419
[20] Ertas I.E., Kahyaoglu S., Yilmaz B., Ozel M., Sut N., Guven M.A., et al.: “Association of maternal serum high sensitive C-reactive protein level with body mass index and severity of pre-eclampsia at third trimester”. J. Obstet. Gynaecol. Res., 2010, 36, 970.
doi: 10.1111/j.1447-0756.2010.01279.x pmid: 20722986
[21] Daniel W. : “Biostatistics. A foundation for analysis in the health science”. 6th ed. NY: John Wiley and Sons, Inc., 1995.
[22] Toptas M., Asik H., Kalyoncuoglu M., Can E., Can M. M.: “Are Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio Predictors for Severity of Preeclampsia”. J. Clin. Gynecol. Obstet., 2016, 5, 27.
doi: 10.14740/jcgo389w
[23] Melet L., Chaigneau C., Lefevre-Pettazzoni M.: “Evaluation of an haematological analyser (Siemens Advia((R)) 2120i) and improving quality of daily practice”. Ann. Biol. Clin. (Paris), 2013, 71, 679.
[24] Jarrett R.J.: “The metabolic syndrome”. Lancet, 2005, 366, 1922.
doi: 10.1016/S0140-6736(05)67780-X pmid: 16325689
[25] Neuhauser H.K.: “The metabolic syndrome”. Lancet, 2005, 366, 1922.
doi: 10.1016/S0140-6736(05)67780-X pmid: 16325689
[26] Yucel B., Ustun B.: “Neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, mean platelet volume, red cell distribution width and plateletcrit in preeclampsia”. Pregnancy Hypertens., 2017, 7, 29.
doi: 10.1016/j.preghy.2016.12.002 pmid: 28279444
[27] Serin S., Avci F., Ercan O., Kostu B., Bakacak M., Kiran H.: “Is neutrophil/lymphocyte ratio a useful marker to predict the severity of pre-eclampsia?” Pregnancy Hypertens., 2016, 6, 22.
doi: 10.1016/j.preghy.2016.01.005 pmid: 26955767
[28] Akıl M.A., Bilik M.Z., Acet H., Tunç S.Y., Ertaş F., Aydın M. et al.: “Mean platelet volume and neutrophil lymphocyte ratio as new markers of preeclampsia severity”. Koşuyolu Heart J., 2015, 30, 5.
[29] Oylumlu M., Ozler A., Yildiz A., Oylumlu M., Acet H., Polat N., et al.: “New inflammatory markers in pre-eclampsia: echocardiographic epicardial fat thickness and neutrophil to lymphocyte ratio”. Clin. Exp. Hypertens., 2014, 36, 503.
doi: 10.3109/10641963.2013.863324
[30] ACOG Committee on Obstetric Practic.: “ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists”. Int. J. Gynaecol. Obstet., 2002, 77, 67.
pmid: 12094777
[31] Kirbas A., Ersoy A.O., Daglar K., Dikici T., Biberoglu E.H., Kirbas O., et al.: “Prediction of Preeclampsia by First Trimester Combined Test and Simple Complete Blood Count Parameters”. J. Clin. Diagn. Res., 2015, 9, QC20.
doi: 10.7860/JCDR/2015/15397.6833 pmid: 26674673
[32] Best L.G., Saxena R., Anderson C.M., Barnes M.R., Hakonarson H., Falcon G. et al.: “Two variants of the C-reactive protein gene are associated with risk of pre-eclampsia in an American Indian population”. PLoS One, 2013, 8, e71231.
doi: 10.1371/journal.pone.0071231 pmid: 23940726
[33] de Jonge L.L., Steegers E.A., Ernst G.D., Lindemans J., Russcher H., Hofman A., et al.: “C-reactive protein levels, blood pressure and the risks of gestational hypertensive complications: the Generation R Study”. J. Hypertens., 2011, 29, 2413.
doi: 10.1097/HJH.0b013e32834c58e5
[34] Cemgil Arikan D., Aral M., Coskun A., Ozer A.: “Plasma IL-4, IL- 8, IL-12, interferon-gamma and CRP levels in pregnant women with preeclampsia, and their relation with severity of disease and fetal birth weight”. J. Matern. Fetal. Neonatal Med., 2012, 25, 1569.
doi: 10.3109/14767058.2011.648233 pmid: 22185464
[35] Cebesoy F.B., Balat O., Dikensoy E., Kalayci H., Ibar Y.: “CA-125 and CRP are elevated in preeclampsia”. Hypertens. Pregnancy, 2009, 28, 201.
doi: 10.1080/10641950802601187 pmid: 19437230
[36] Guven M.A., Coskun A., Ertas I.E., Aral M., Zencirci B., Oksuz H.: “Association of maternal serum CRP, IL-6, TNF-alpha, homocysteine, folic acid and vitamin B12 levels with the severity of preeclampsia and fetal birth weight”. Hypertens. Pregnancy, 2009, 28, 190.
doi: 10.1080/10641950802601179 pmid: 19437229
[37] Ustün Y., Engin-Ustün Y., Kamaci M.: “Association of fibrinogen and C-reactive protein with severity of preeclampsia”. Eur. J. Obstet. Gynecol. Reprod Biol., 2009, 121, 154.
doi: 10.1016/j.ejogrb.2004.12.009 pmid: 16054955
[38] Djurovic S., Clausen T., Wergeland R., Brosstad F., Berg K., Henriksen T.: “Absence of enhanced systemic inflammatory response at 18 weeks of gestation in women with subsequent pre-eclampsia”. BJOG, 2002, 109, 759.
doi: 10.1111/j.1471-0528.2002.01330.x pmid: 12135211
[39] Savvidou M.D., Lees C.C., Parra M., Hingorani A.D., Nicolaides K.H.: “Levels of C-reactive protein in pregnant women who subsequently develop pre-eclampsia”. BJOG, 2002, 109, 297.
doi: 10.1111/j.1471-0528.2002.01130.x pmid: 11950185
[1] H.M. Kim, Y.S. Choo, W.J. Seong. Serum NT-proBNP levels as a marker for cardiopulmonary function in preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 511-515.
[2] H. Yolli, M.E. Demir, R. Yildizhan. Neutrophil gelatinase associated lipocalin-2 (Ngal) levels in preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 519-523.
[3] J. Yoon Park, S.W. Lee, K.J. Oh, J.-S. Hong. High mean blood pressure during the first trimester is predictive of future preeclampsia development in healthy pregnant women: a cohort study in Korea[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 770-775.
[4] Y.E. Purut, E.E. Buyukbayrak, F. Ercan, A. Orcun, M. Menke, A.Y. Karageyim Karsidag. Do first trimester maternal serum follistatin like 3 levels predict preeclampsia and/or related adverse pregnancy outcomes?[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 195-200.
[5] E. Ertekin, Ö. Tunçyürek, S. Kafkas, Y. Özsunar. Does the placental strain ratio correlate with the umbilical artery Doppler values?[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 227-230.
[6] A. Simsek, S. Uludag, A. Tuten, A. S. Acikgoz, S. Uludag. Maternal and perinatal outcomes in early onset and late onset preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(6): 837-841.
[7] B. Dullaert, S. Schroven, Y. Jacquemyn. The effect of maternal vitamin D status on pregnancy outcome and child health in the first year of life[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 677-681.
[8] Jinqi Ma, Hua Yao. Persistent hypertension post-preeclampsia: a tertiary care centre-based study in China[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 741-744.
[9] R. Einikytė, A. Dapkeviciute, V. Dzenkeviciute, S. Kasnauskiene, V. Sapoka, D. Ramasauskaite. The importance of angiogenic and antiangiogenic biomarkers in pathogenesis and early diagnosis of preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(4): 485-492.
[10] H. Kobayashi, T. Tsunemi, J. Akasaka, N. Koike, A. Shigemitsu. F. Ito, Y. Yamada, E. Fujii. Preeclampsia as a parental epigenetic disease[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(4): 493-502.
[11] A. Jafari, S. Parchami, S. Reiisi, S. Miraj. Association of plasma homocysteine, folic acid levels, and C677T polymorphism in methylene tetra hydrofolate reductase with risk of preeclampsia: a case-control study in Iranian women[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(3): 367-374.
[12] E. Shim, J.Y. Park, H.J. Seol. Placental expression of retinol-binding protein 4 in patients with preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(1): 98-101.
[13] R. Lukic, M. Djukic, I. Soldatovic, N. Karadzov Orlic, D. Ardalic, G. Dragovic, Z. Mikovic. Prediction of preeclampsia using extreme first-trimester PAPP-A, free βhCG and uterine artery Doppler in resource limited settings[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(6): 851-855.
[14] T. Tsunemi, T. Sado, K. Naruse, H. Kobayashi. Paternal contribution to the preeclampsia phenotype[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(6): 914-922.
[15] Peng Zhang, Qi-wen Wu, Gang Feng, Chun-sheng Liu, Ying-ying Zhang, Chun Pu. Protein Z and anti-protein Z IgG levels, but not the promotor A13G polymorphism, are associated with preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(6): 929-933.
No Suggested Reading articles found!